Aisling Capital believes the next decade will be marked by a revolution inhealthcare driven by new therapeutics generated by biotechnology.

　　The completion of the human genome has given scientists new insights intothe causes of human disease.

　　These insights, combined with the past 20 years of developments in thebiotechnology industry, are leading to rapid expansion of novel approachestoward the diagnosis, prevention, and treatment of life-threateningillnesses.

　　These advances have led to an ever-increasing demand for capital tocomplete the development and commercialization of new therapeutics.

　　Our goal is to support the leading global healthcare companies that arebuilding on these technical and medical breakthroughs to commercialize newhealthcare products.